Literature DB >> 6355100

Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism.

P O'Looney, M Vander Maten, G V Vahouny.   

Abstract

Recirculating organ perfusion in vitro was conducted with hearts from control rats, animals given a single dose of streptozotocin (65 mg/kg) 48 h earlier, and streptozotocin-treated rats administered insulin (5 units), 2 h prior to organ perfusion. During 45-min perfusions, the lipolysis of very low density lipoprotein (VLDL) triglyceride was significantly less in hearts from diabetics than in controls (41.9 +/- 7.3% of control). This was associated with significant reductions in heparin-releasable (functional) lipoprotein lipase and tissue lipoprotein lipase of perfused hearts. The decreases in VLDL triglyceride metabolism and the levels of myocardial lipoprotein lipase were completely reversed by treatment of diabetic rats with insulin 2 h prior to study. Similar improvement of VLDL triglyceride metabolism and increases in myocardial lipoprotein lipase activity were observed in hearts from diabetic rats by direct addition of 100 milliunits/ml of insulin to the recirculating perfusion media. Under these conditions, the increase in both fractions of lipoprotein lipase in response to insulin was completely inhibited, and utilization of VLDL triglyceride was partially inhibited by pre-perfusion with cycloheximide for 10 min. The data derived from either VLDL triglyceride lipolysis in organ perfusion or direct measurement of myocardial lipoprotein lipase demonstrate a direct effect of insulin on myocardial lipoprotein lipase activity, and suggest that the response to insulin may be due in part to effects on protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355100

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Regulation of the synthesis, processing and translocation of lipoprotein lipase.

Authors:  J E Braun; D L Severson
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

2.  The changes in plasma lipoproteins in rat with diabetes induced by streptozotocin.

Authors:  G Cheng; Z C Feng; Y T Huang
Journal:  J Tongji Med Univ       Date:  1988

3.  Insulin and dexamethasone stimulation of cardiac lipoprotein lipase activity involves the actin-based cytoskeleton.

Authors:  H S Ewart; D L Severson
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

Review 4.  Metabolic disturbances in diabetic cardiomyopathy.

Authors:  B Rodrigues; M C Cam; J H McNeill
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Lipoprotein lipase activity in rat cardiomyocytes is stimulated by insulin and dexamethasone.

Authors:  H S Ewart; R Carroll; D L Severson
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

6.  Post-transcriptional mechanisms are responsible for the reduction in lipoprotein lipase activity in cardiomyocytes from diabetic rat hearts.

Authors:  R Carroll; L Liu; D L Severson
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

7.  Effect of diabetes on acid and neutral triacylglycerol lipase and on lipoprotein lipase activities in isolated myocardial cells from rat heart.

Authors:  I Ramírez; D L Severson
Journal:  Biochem J       Date:  1986-08-15       Impact factor: 3.857

8.  Regulation of lipoprotein lipase in the diabetic rat.

Authors:  K Tavangar; Y Murata; M E Pedersen; J F Goers; A R Hoffman; F B Kraemer
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 9.  Endothelium, the dynamic interface in cardiac lipid transport.

Authors:  R O Scow; E J Blanchette-Mackie
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

10.  The effect of prolonged hyperglycemia on metabolic alterations in the subtotally pancreatectomized rat.

Authors:  Y Noguchi; R N Younes; K C Conlon; N A Vydelingum; A Matsumoto; M F Brennan
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.